InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,220.00
(
-0.20%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.39
(
0.00%
)
Bitcoin
64,385.80
(
0.22%
)
Post# of 252302
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DonShimoda

Send PM Follow Ignore
Followers 19
Posts 727
Boards Moderated 0
Alias Born 11/10/2009

DonShimoda

Re: jq1234 post# 151273

Friday, 10/26/2012 10:01:51 AM

Friday, October 26, 2012 10:01:51 AM

Post# of 252302
I believe the market is going to stratify along two-lines with the majority of patients WW continuing to start on gleevec, or its generic equiavalent, and (based on the new NCCN guidelines in CML) move to ponatinib in 2nd-line. Furthermore, I believe this can be accomplished without running a large multi-arm sprycel/tasigna head-to-head trial.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up